FIELD LOG / LENS: USE & MECHANISM
What Is Semax Peptide Used For? The Research
The structure, the studied uses, and the mechanism — read off the published record, with the variants the research community discusses.
The gist
If you have searched what is semax peptide used for, here is the plain version. Semax is a lab-made peptide first studied in Russia. In Russia and Ukraine it is a prescription medicine used for stroke recovery, a brief stroke-like event called a transient ischemic attack, certain cognitive problems, and an eye-nerve disease. Everywhere else — including the United States — it is not an approved drug at all; it is sold only as a research chemical.
In the lab, researchers study it for two main things. First, as a nootropic: a substance looked at for better focus, memory, and learning. Second, as a neuroprotective agent: something that may help brain cells survive injury, mainly tested in animal stroke models. The way it seems to work is by raising the brain's own growth signals (BDNF and NGF) in specific regions. Below is what that actually means.
What is semax used for
In the published record, Semax is used in two settings that should not be confused. The first is clinical use in Russia and Ukraine, where it is a registered prescription drug for ischemic stroke, transient ischemic attack, cognitive impairment, and optic-nerve disease, and where it sits on Russia's List of Vital and Essential Drugs. A clinical study reported a therapeutic effect in optic-nerve disease, one of those registered indications [14], and early human work documented Semax-associated changes on the EEG [13].
The second is research use everywhere else, where Semax is an unscheduled research chemical with no approved human indication. In that context it is studied — overwhelmingly in rodents — as a nootropic and neuroprotective peptide. The studied applications are cognition and memory tasks, neuroprotection in cerebral ischemia, and antidepressant- and anxiolytic-like effects in stress models. No published Western randomized controlled trials exist, and there are no controlled human trials specifically for ADHD, Parkinson's, or Alzheimer's disease.
The structure, kept plain
Semax is a single chain of seven amino acids: Met-Glu-His-Phe-Pro-Gly-Pro. Read it as two parts. The front, Met-Glu-His-Phe, is the ACTH(4-7) fragment — a natural piece of the hormone ACTH that carries brain-signaling activity but, on its own, breaks down too fast to be useful. The back, Pro-Gly-Pro (PGP), was grafted on by chemists to slow that breakdown. The result is more stable than the bare fragment, and the PGP tail turns out to be biologically active in its own right.
What Semax does not have matters as much as what it does. It lacks the cortisol-releasing (steroidogenic) action of full-length ACTH — so it is not a stress-hormone drug. Its molecular weight is 813.9 Da; it is commonly supplied as the acetate salt and as a freeze-dried (lyophilized) powder.
How the mechanism reads
The clearest mechanistic signal is neurotrophic. Semax rapidly and region-specifically raises BDNF and NGF — the brain's growth and maintenance signals for neurons. It increased BDNF protein in rat basal forebrain at 3 hours and bound a specific, reversible, calcium-dependent site with a dissociation constant of 2.4 nM [1], and it regulated BDNF together with its receptor TrkB in the hippocampus [9]. A single intranasal dose moved NGF and BDNF mRNA up in some regions and down in others [2] — region-specific, not blanket.
A second action is enzyme inhibition: in human serum Semax blocked enkephalin-degrading enzymes (IC50 ~10 microM) [3], which would prolong the brain's natural opioid signaling. A third, more recently characterized in vitro property is high-affinity copper binding, which can strip copper from amyloid-beta and cut copper-driven oxidative damage — interesting, but its relevance at real in-vivo doses is not yet established. At the cellular level, Semax protected cultured PC12 cells from oxidative-stress death [12].
What the studies actually tested it for
Beyond the broad labels, it helps to see the specific endpoints researchers measured, because that is what 'used for' really means in a lab. In neuroprotection, the work is concrete: 6 days of intranasal Semax reduced cortical infarct volume and preserved memory in a rat model of focal prefrontal-cortex ischemia [4], and genome-wide analysis after middle-cerebral-artery occlusion tied that protection to shifts in immune and vascular genes rather than a single receptor [5]. At the cellular level, Semax kept cultured rat PC12 cells alive under oxidative stress [12].
In cognition and memory, the endpoints are behavioral and molecular together: Semax prevented learning and memory inhibition caused by heavy metals in rats [10], while the BDNF, NGF, and TrkB changes [1][2][9] supply the mechanism that would underpin such effects. A 2025 study reported that Semax and a derivative improved cognition and reduced amyloid inclusions in an Alzheimer's animal model [16] — a genuinely current result, and still strictly preclinical. None of these endpoints amounts to an approved human use; they are what the research has measured, which is a different and more honest claim.
N-Acetyl Semax Amidate
The research community frequently discusses a modified version called N-Acetyl Semax Amidate. The name describes two chemical changes to the ends of the molecule: an acetyl group added to the N-terminus and an amide cap on the C-terminus. Both modifications are intended to slow enzymatic breakdown relative to unmodified Semax, on the same logic that put the Pro-Gly-Pro tail on the original — make the peptide last longer against the enzymes that chew it up.
It is important to be honest about the evidence here. The detailed pharmacology summarized across this site — the 2.4 nM basal-forebrain binding [1], the neurotrophin gene-expression shifts [2], the ischemia neuroprotection [4] — was conducted on Semax itself, not on the N-acetyl amidate variant. The variant is a frequent subject of community interest and is sold as a research chemical, but it does not carry an equivalent independent published record. Treat claims that map the original Semax findings directly onto the variant with caution.